Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L7MP
|
|||
| Drug Name |
3-acylidene-2-oxoindole derivative 2
|
|||
| Synonyms |
PMID26560530-Compound-30
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
NUMERATE, INC. THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY GRIFFIN, John RAIMUNDO, Brian MADRID, Peter KHOSLA, Chaitan JIN, Xi KLOECK, Cornelius
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H12ClNO3
|
|||
| Canonical SMILES |
COC1=CC=CC=C1C(=O)C=C2C3=C(C=CC=C3Cl)NC2=O
|
|||
| InChI |
1S/C17H12ClNO3/c1-22-15-8-3-2-5-10(15)14(20)9-11-16-12(18)6-4-7-13(16)19-17(11)21/h2-9H,1H3,(H,19,21)/b11-9+
|
|||
| InChIKey |
ULAXMAMZNHGQMV-PKNBQFBNSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.